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ABSTRACT

Bates, Mallory, N. M.S.B.M.E., Department of Biomedical, Industrial, and Human
Factors Engineering, Wright State University, 2022. Development of Gene Regulatory
Elements for Biosensing Applications

21% of U.S adults experienced mental illnesses in 2020. Nearly 1 in 4 active- duty
military personnel showed signs of mental health conditions in 2014 [89]. Mental health
can be identified in the body by different biomarkers. These biomarkers potentially could
be controlled by riboswitches, which could help mental illnesses and regulate diseases.
Riboswitches are desirable in these cases due to responding without affecting vital
functions. Riboswitches are located in mRNA and switch “ON” or “OFF” depending on
the concentration of a biomarker [13]. In this research, riboswitches were re-engineered
to take a known riboswitch and control its response in the presence of a biomarker. This
was done by computationally changing PreQ1, a known riboswitch that has the smallest
aptamer, and then experimentally testing against biomarkers, dehydroepiandrosteronesulfate (DHEA-S), Serotonin, Cortisol, Dopamine, Epinephrine, and Norepinephrine.
A total of 7 variant riboswitches were tested in this research, 4 created
computationally and 3 created in research [53]. The results from these variants showed
that variants 1 and 2 had different responses to DHEA-S then the expected PreQ1
response. A dose response test confirmed this by having a downward trend as DHEA-S
concentration increased. In conclusion of this research, riboswitches can be re-engineered
to have a different response to biomarkers but keep the same structure.
iii
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1. Introduction
The body has self-made processes to help regulate different levels of proteins,
analytes, and many other cellular metabolites. This prevents systems from deteriorating
and helps keep homeostasis throughout the body. An example of this system in action
would be if there was a high of serotonin in the body. A biomarker would recognize this
surplus and transmit data to all systems that can regulate serotonin. The regulation part of
this system would tell the body to stop producing serotonin and in addition have the body
reduce the surplus as well.
In the above example, riboswitches would help regulate the serotonin through
RNA. An analyte or biomarker would bind to the aptamer of the riboswitch. The
riboswitch would respond through producing proteins or stopping the production.
Depending on the purpose of the riboswitch, proteins that would be produced would help
decrease the surplus serotonin. If the riboswitch stops producing proteins, then the
riboswitches’ purpose would be to help production of serotonin.
Riboswitches are RNA-based biological sensing elements that bind with
metabolites without the need for protein involvement [58, 79]. They are used to regulate
levels of biomarkers through the expression of proteins [61]. There are 17 different types
of riboswitches that have been discovered and more than 100 are continuing to be
experimentally validated [61]. Synthetic riboswitches are being engineered to help with
gene therapy [8].
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Biomarkers are cellular, biochemical, or molecular alterations measured in
biological media, such as human tissues, cells, or fluids [19]. These markers have been
studied as potential medical signs leading to disease. Biomarkers can be used to explain
changes in the body that lead to mental illnesses, cardiovascular disease, and specific
types of cancer [4]. Riboswitches can be used to regulate biomarkers. Identifying
riboswitch and biomarker connections will lead to the regulation of these biomarkers [3].
In this research, different biomarkers will be tested against one riboswitch. After
manipulating the riboswitch, the biomarkers response will be recorded.
PreQ1 is the riboswitch used in this research. It was chosen due to having the
smallest known aptamer with 34 nucleotides [23]. The biomarkers examined in this
research are dehydroepiandrosterone-sulfate (DHEA-S), Serotonin, Cortisol, Dopamine,
Epinephrine, and Norepinephrine. The biomarkers are shown in Table 1 along with
related health conditions they influence.
Biomarker

Related health condition(s)

DHEA-S

Cognitive function [26]

Serotonin

Mood regulation, appetite, antidepressant [69]

Cortisol

Stress hormone, acute stress, low-blood glucose, obesity,
depression, diabetes [47,69]

Dopamine

Feelings of happiness [69]

Epinephrine

Drives automatic nervous system emergency response,
increases heart rate, blood pressure [69]

Norepinephrine

Stress hormone, high glucose, increased heart rate, anxiety,
high blood pressure [69]

Table 1: Biomarkers and their related health conditions
2

Synthetic riboswitches could be extended to work with biomarkers to help with
mental illnesses and regulate diseases. In 2020, twenty one percent of U.S adults
experienced mental illnesses (52.9 million people). People with depression have a 40%
higher risk of developing cardiovascular and metabolic diseases [89]. Nearly 1 in 4
active-duty military personal showed signs of a mental health condition in 2014 [89].
Using riboswitches as a potential way to solve problems is desirable because they can
respond without affecting vital functions. Each riboswitch has different variants that
respond in the same manner. A synthetic riboswitch would have the same design in the
RNA makeup but would respond inversely. This can be done through the aptamer section
of the riboswitch [81].
1.1 Motivation
The motivation behind this project was to engineer a variant riboswitch that has
the structure of PreQ1 but acts the reverse in the presence of biomarkers. This would
show that it is possible to create a synthetic riboswitch from a known structure to change
the outcome of proteins. From previous research, an approach that combines
computational software and experimental data has shown to create such riboswitch.
PreQ1 is known to have a small aptamer with less nucleotides compared to other
riboswitches [26,69].
In addition to a small aptamer, PreQ1 has an ideal structure of the aptamer, which
will be helpful when creating different designs in software. PreQ1 has also been
researched with the purpose of creating synthetic designs [72]. This research will be
3

referred to, as well as variants already created [53]. Known and newly created variants
will be tested with the same biomarkers to compare as well.
The tests that will be used in this research are known procedures. This will help
eliminate multiple variables needed to be modified and keep the focus of this research on
the design and success of the variant riboswitches.
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2. Literature Review
2.1 Riboswitches
A riboswitch is made of two parts; an aptamer and expression platform, located
within the mRNA [15]. A riboswitch operates when a metabolite abundance meets a
threshold, the ligand binds to the aptamer [60]. This leads to a downstream affect by the
expression platform with a conformational change [2]. The conformational change
generates the expression platform to either be in an “ON” or “OFF” state [61]. Aptamers
bind to ligands with affinities and selectivity [6]. The complexity of the aptamer and
ligand separately make it challenging to engineer [5]. Every riboswitch will be
reengineered differently based on the chemical composition of that specific riboswitch
[62]. Although a significant amount of research has been done, due to the specific
methods needed, most aptamers have not been converted to functional riboswitches [56].
“Existing approaches rely on qualitative design by experts, combinational library
generation and high-throughput screening, which have limited the breadth of riboswitchbased applications [12].” There is no way to predict ligand specificity through aptamer
sequences [24].
Riboswitches have a wide range of classes with representatives within. Ronald R
Breaker has distributed these classes and ligands [51, 71]. There are coenzymes, amino
acids, signaling molecules, ions, nucleotide derivatives, and other metabolites [52].
Riboswitches are mostly found in bacteria [7]. “In the case of Bacillus subtilis, more than
4% of genes are predicted to be under the regulation of riboswitches and assorted cis5

regulatory elements” [24]. In 2012, Breaker stated there was currently 17 experimentally
validated riboswitch classes and potentially more than 100 classes still awaiting
discovery [32, 61]. Each riboswitch class can have multiple representatives, for example
the TPP riboswitch has more than 15,000 representatives that are known [36, 39]. The
structure of each riboswitch is made up of different nucleotides: adenine, uracil, cytosine,
and guanine [44]. The bonding of these nucleotides’ forms knotting and folding of the
riboswitch [54].
Riboswitches can be placed into two large groups: pseudoknotted and junctional
riboswitches [45]. A pseudoknotted riboswitch is “predominantly on the basis of a single
pseudoknot, a knot-shaped conformation formed through base pairing between a loop of
an RNA stem-loop structure and an outside region” [82]. “Junctional riboswitches
contain a multi-helical junction which connects various numbers of helices” [82]. Other
than psuedoknots and junction loops; hairpins, stem loops, and kissing loops are also
structural elements. These can also play a part in different bonding [73].
Bonding in riboswitches is one controlling factor for ligand affinity [67].
Hydrogen bonding is most important for specificity of recognition to the ligand [83].
Ligands have donors and acceptors for hydrogen bonding [76]. When reengineering
riboswitches, changing a nucleotide can change the geometric shape and leads to the
recognition of the ligand [35, 40]. Hydrogen bonding is a dipole-dipole attraction
between molecules. This attraction comes from a hydrogen molecule and an
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electronegative molecule such as oxygen, nitrogen, or fluorine [43]. For RNA, the
nitrogen bases are helping to form temporary hydrogen bonds [82].
In Figure 1, riboswitch diversity is shown. This image also shows the mechanisms
of gene control in bacteria. The portion that will be used in this research is in the section
A of the image. The figure shows how the aptamer encounters the ligand and from there
responses are shown. The response is based on the riboswitch. The aptamer and ligands
affinity and sizes determine if they would come into contact [1].

Figure 1. Diversity of riboswitches [2]
7

2.2 PreQ1
PreQ1 is known from its interaction to produce the hypermodified guanine
nucleotide, queuosine (Q). This is a multistep reaction that starts with GTP then going to
PreQ0 and PreQ1 to end in Q, as shown in Figure 2.

Figure 2. Schematic diagram of queuosine-precursor and preQ1 riboswitch organization
[23]

There are two different subclasses of PreQ1 based on where they are found, type I and II.
Type I is found in T. tengcongensis and type II in Bacillus subtilis [57]. Type I is
involved in translational regulation and type II in transcriptional regulation [84, 86]. Both
types of aptamers are H-type pseudoknots, but for type II the presence of a ligand causes
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conformation changes when bonded [85]. For example, in Bacillus subtilis when PreQ1
binds to the ligand, the riboswitch folds into an H-type pseudoknot [58]. This folding
causes a conformational change into a terminator hairpin. PreQ1 bonded with the ligand is
considered “ON” and gene expression is terminated in this situation. When the ligand is
not bonded, the riboswitch is “OFF”, and gene expression continues.
In this research, the aptamer domain was changed in different forms. This
followed the process that was used in the article, Rational Re-engineering of a
Transcriptional Silencing PreQ1 Riboswitch [53]. In this study, three different
riboswitches were created from PreQ1. Figure 3 shows the aptamer domain of PreQ1. The
aptamer domain for this riboswitch has one loop shown. When re-engineering this, the
loop had to be sustained.

9

Figure 3. Structure of PreQ1 Aptamer [53]

2.3 Biomarkers
“A defined characteristic that is measured as an indicator of normal biological
processes, pathogenic processes, or responses to an exposure or intervention, including
therapeutic interventions. Molecular, histologic, radiographic, or physiologic
characteristics are types of biomarkers [69].” This is a general definition of biomarkers
from the American National Institute of Health (NIH) and the Food and Drug
Administration (FDA). Types of biomarkers are hormones, neurotransmitters, enzymes,
10

and metabolites [17, 74]. Biomarkers can range is size and weights as they are made up
of molecules of different sizes [69]. Depending on these factors, riboswitch aptamers can
bind based on their affinities for each biomarker [14, 48]. If there is a high concentration
of a biomarker, a riboswitch aptamer could bind to it and a conformational change would
occur. This would lead to the expression platform of the riboswitch to react. As stated
above, an expression platform would then have multiple different responses based on the
bonding. The image below shows how biomarker react with different areas of the body,
Figure 4. This will be discussed in the specific biomarker sections as well.

Figure 4. Anatomical schematic of endocrine and nervous systems [69]

In the article, Stress Biomarkers in Biological Fluids and Their Point-of-Use
Detection, stress biomarkers are described [69]. For hormones and neurotransmitters,
biomarkers are involved with the endocrine and nervous systems. As stress is a hormone
biomarker, the article explains how stress affects the body and travels when released. The

11

article talks about a general observation of biomarkers. These biomarker concentrations
range over 6 orders, higher concentrations usually lead to smaller molecules, molecular
weight tends to decrease the concentration [69]. Some of the most common biomarkers
are serotonin, dopamine, and cortisol [87].
Cortisol has shown to play a positive role in physical performance [20]. As stated
in the article, cortisol is involved in catabolic metabolism. A ratio of cortisol with
testosterone can be used as a tool to detect overtraining. In this article, soccer players
were tested after a tournament, players did performance testing and then gave blood and
saliva samples [20]. The results from this study showed that biomarkers had correlations
to hematological, inflammatory, and endocrinological markers. This test did have
limitations to sample size, age, and category. Markers that were looked at in this study
that showed to be significant were cortisol, testosterone, creatine kinase, sex hormones,
cytokines, hematological panels, and nutritional markers. Creatine kinase is a biomarker
for skeletal muscle damage. This marker should increase after a training session. Cortisol
and testosterone are usually looked at for prolonged physical stress. By looking at a panel
of multiple biomarkers, performance could be examined [18].
Biomarkers are described in, Biomarkers of physical activity and exercise [16].
Cortisol, testosterone, lactate, creatine kinase, creatinine, ammonia, lactate
dehydrogenase, uric acid, urea, homocysteine, cardiac troponin, malondialdehyde and
protein carbonyls, superoxide dismutase and glutathione peroxidase, reactive oxygen
species, C-reactive protein, interleukin-6, and leukocytes are explained in this article.
12

They are broken down through areas of the body they affect [38]. Biomarkers also have
chemical background within the body [25]. Solubility is based on the molecular structure
of the biomarker.
Biomarkers that are used in this study are Cortisol, Serotonin, Dopamine,
Epinephrine, Norepinephrine, and DHEA-S. Each of these biomarkers will be briefly
described along with their chemical structure.
2.4 Cortisol
Cortisol is released from adrenal glands through activation of the hypothalamicpituitary-adrenal axis [11]. It is a glucocorticoid steroid hormone with the primary
function to increase blood sugar. It does this through the process of gluconeogenesis [66].
The chemical structure of cortisol is shown below in Figure 5.

Figure 5. Chemical structure of cortisol
13

Cortisol is known to be a biomarker for stress. An acute high level of cortisol is
used for survival. Prolonged stress or high levels of stress can deteriorate the body and
cause physiological problems. These situations are where cortisol is at a chronic high
level. Mental issues can arise from chronic high levels of cortisol as well.
2.5 Serotonin
Serotonin has various roles like vascular resistance and blood pressure. It also can
be related to virtually all major organ systems. Serotonin is produced in the central
nervous system [77]. The chemical structure of serotonin is shown below in Figure 6.

14

Figure 6. Chemical structure of serotonin

Serotonin regulates behavioral and neuropsychological processes such as mood,
perception, reward, anger, aggression, appetite, memory, sexuality, and attention. Mental
illnesses like anxiety are treated through drug that target serotonin receptors.
2.6 Dopamine
Dopamine can be seen in many roles in the body. The dopaminergic system is
when dopamine is involved as a neurotransmitter. This system plays roles
neuromodulation and influences different immune systems [30]. For neuromodulation the
following are included: movement and motor control, spatial memory function,
motivation, arousal, reinforcement, reward, sleep regulation, attention, affect, cognitive
function, feeding, olfaction, and hormone regulation. Immune systems that are involved
are cardiovascular, gastrointestinal, and renal. The chemical structure of dopamine is
shown below in Figure 7.

15

Figure 7. Chemical structure of dopamine

2.7 Epinephrine & Norepinephrine
Epinephrine and norepinephrine are synthesized from dopamine. They both bind
to adrenergic receptors [55]. Epinephrine has a fast and short stress-response signal.
These two differ by a methyl group on the nitrogen side chain. This is shown in the
figures below, the chemical structures for both are shown.

16

Figure 8. Chemical structure of epinephrine

Figure 9. Chemical structure of norepinephrine
17

2.8 DHEA-S
DHEA-S is produced by the adrenal glands in women and men. It is a protective
anabolic hormone with its role of maintaining and restoring the human body. The
chemical structure of DHEA-S is shown below in Figure 10.

Figure 10. Chemical structure of DHEA-S

2.9 Reengineering Riboswitches
There are known methods for synthetically developing riboswitches and ligands
[27]. One method is the SELEX (Systematic Evolution of Ligands by Exponential
Enrichment) [22, 88]. This is an in vitro selection method commonly used for aptamers
[73]. The SELEX method consists of three steps: selection, portioning, and amplification
[9]. This is shown in the below image, Figure 11.

18

Figure 11. Schematic illustration of the SELEX process for the DNA and RNA library

Methods involving engineering riboswitches varies for each type. One method
that took a natural reengineer path over creating a synthetic riboswitch is in the article
[34]. A secondary structure was created with biological sources that host multiple
aptamers [34]. The purpose of this research was to create a riboswitch that would, when
bonded with the ligand, turn “ON”. The article mentions using natural RNA elements has
more advantages over computational. Ceres et al. thought to bind a biological structure to
the aptamer. This would then change the expression platform. The results for this
research were extensive, due to the wide range of riboswitches that needed to be tested.
As they wanted to engineer a natural “OFF” switch to be an “ON” switch, specific classes
needed to be chosen. In the article, two modular “ON” switches were made [34]. One
drawback from this research is that these methods can be referred to but will need major
19

adjustments for each riboswitch. A predictable regulatory system will most likely come
from in vivo research based on the article Computational analysis of riboswitch-based
regulation [24, 64].
A method that was used in Design of Mammalian ON-Riboswitches Based on
Tandemly Fused Aptamer and Ribozyme used twister ribozymes [28]. In this article, a
ribozyme and aptamer were “fused in tandem” and by fusing, it forms an aptazyme. This
structure can take on the form of only the ribozyme or the aptamer. Depending on the
form it takes, while being placed upstream of the aptamer, it will either turn the
riboswitch in an “ON” or “OFF” form [10]. This article was submitted in 2019 and within
recent literature, ribozymes/aptazymes have become popular in research on riboswitches.
A guanine aptamer was experimented with a twister ribozyme [28]. The results show that
based on the stability of the aptamer dictates whether the aptazyme will take on the
characteristics of the aptamer of ribozyme. This article shows a different method than
Ceres et al. and one major difference is the use of ribozymes. Ceres et al. method was to
bind to biological elements, ribozymes were not used. The same problem does arise in
Mustafina et al. research like Ceres et al. by each riboswitch will need different methods
and new experimentation.
Alternately, Automated physics-based design of synthetic riboswitches from
diverse RNA aptamers, uses a computational approach. The approach that was taken in
this article stems from experimental aptamers not being transitioned to functional
riboswitches [12]. This is due to “the qualitative design by experts, combinatorial library
20

generation and high- throughput screening” Though this article is not looking at reengineering a riboswitch, it is finding a computational model to predict the function of
the riboswitch. Espah Borujeni et al. validated 77 synthetic riboswitches with diverse
aptamers [12]. Through measuring free energy, equations were created and proven to
predict riboswitch activation [50]. Using the model, an algorithm was created to convert
RNA aptamers into synthetic riboswitches. This research statistically finds different RNA
aptamers and can create a functional riboswitch through modeling [65]. One restriction to
this research is that the research is computational and not tested on bacteria culture. The
article states the model assumes thermodynamic equilibrium between the ribosome,
mRNA, and ligand [12]. Computational is a good way to start the research, but without
predicting mRNA stability it can’t be put in place. In Computational analysis of
riboswitch-based regulation, they agree that using a computational model is the best way
to predict a riboswitch structure. It also mentions that when a computational model is
used in conjunction with functional evidence, it is more powerful in detecting regulatory
sequences [24].
Through the research discussed above, a computational design followed by
laboratory procedure is supported [29]. A computational design saves resources by
creating a base design [59]. The common method seen is a mix and match of
computational design and laboratory procedures. By having software as a preliminary
output for that method, less laboratory trials would be needed. A laboratory follow up can
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then test the riboswitch for how it responds. These two methods can also then be
compared, for how the energy levels differ.

22

3. Methodology
3.1 Experimental design:
The experimental design for this research was to create riboswitch designs for
PreQ1 computational through the programs KineFold and NUPACK. Four riboswitch
strands were created, and three riboswitch strands were from research [53] to test as well.
These strands were then prepared to test against the original PreQ1 strand with different
biomarkers. This is further explained below.
3.2 Riboswitch structure modeling:
Computational biology was used to predict riboswitch behavior with different variant
sequences. NUPACK and KineFold were software’s that provided data for these
predictions. These computational models were used by inserting an RNA sequence and
outputting different statistics on each sequence. Using those statistics. Predictions could
be made with how the experimental results could respond.
Riboswitch variants were designed, based on the aptamer layout for PreQ1. Variants 1-4
were designed to have 22 nucleotides and be able to design a loop compared to the
original in KineFold. By exchanging different nucleotides in the original, each variant
was created. Figure 13-16 shows the KineFold simulations, which were compared to the
original in Figure 12. KineFold shows the Free energy of each simulation and is shown
on the bottom of the figures. Variants 5-7 were pulled from the cited research. Table 5
shows the sequences of each variant.
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Figure 12. PreQ1 riboswitch simulation made on KineFold
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Figure 13. Variant 1 simulation made on KineFold
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Figure 14. Variant 2 simulation made on KineFold
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Figure 15. Variant 3 simulation made on KineFold

Figure 16. Variant 4 simulation made on KineFold

3.3 Plasmid constructs:
All plasmids were constructed by isothermal (Gibson) assembly using NEBuilder HiFi
DNA Assembly Master Mix (New England Biolabs, Ipswich, MA). PCR primers and
gBLOCK DNA fragments (serving as DNA templates) were obtained from Integrated
DNA Technologies (Coralville, IA). Plasmid manipulations were performed using MAX
Efficiency DH5α chemically competent E. coli cells (Invitrogen, Carlsbad, CA).
Plasmid pPreQ1-sfGFP: The plasmid pJBL7010 (Addgene, Watertown, MA) containing
sfGFP encoding sequence under control of bacterial J23119 promoter was used to insert
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PreQ1 riboswitch sequence and create the plasmid pPreQ1-sfGFP. The plasmid
pJBL7010 was linearized by using PCR with forward (5’ATGAGCAAAGGTGAAGAACTGTTTACC-3’) and reverse (5’ACTAGTATTATACCTAGGACTGAGCTAGCTGTCAA-3’) primers. PreQ1
riboswitch sequence was amplified in PCR reaction from a single stranded DNA
fragment (5’AAGTGAAAAAATTGAAGAAAATCCGTGCGATATGCGGGAGAGGTTCTAGCTA
CACCCTCTATAAAAAACTAAGGACGAGCTGTATCCTTGGATACGGCCTTTTTT
CGTTATGGCAGGAGCAAACT-3’) using forward (5’CTCAGTCCTAGGTATAATACTAGTAAGTGAAAAAATTGAAG-3’) and reverse
(5’- GTTCTTCACCTTTGCTCATAGTTTGCTCCTG-3’) primers. PCR allows the
addition of overlapping sequences (underlined) (required for Gibson Assembly-based
ligation) to the ends of amplified products. Both PCR reactions were performed in 50 µl
volume using 1 ng/µl DNA template (pJBL7010 or PreQ1 DNA fragment), 0.2 µM
primers, 200 µM dNTPs, 1X HF Buffer (New England Biolabs, Ipswich, MA), 3%
DMSO, and 0.5 µL (1.0 units) Fusion High-Fidelity DNA Polymerase (New England
Biolabs, Ipswich, MA). The PCR reactions were performed in thermocycler using
conditions presented in Table 2 and Table 3.
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Table 2. Thermocycling conditions for amplification of pJBL7010.
Number of Cycles
Program
1

98 ºC for 30 s

29 cycles

98 ºC for 10 s, 53 ºC for 30 s, 72 ºC for 5

1

s

End

72 ºC for 10 min
4 ºC

Table 3. Thermocycling conditions for amplification of PreQ1 sequence.
Number of Cycles
Program
1

98 ºC for 30 s

29 cycles

98 ºC for 10 s, 53 ºC for 30 s, 72 ºC for 5

1

s

End

72 ºC for 10 min
4 ºC

PCR products were analyzed by standard 1% agarose gel electrophoresis (Figure 17). 0.5
g agarose were added to 50 mL 1X Tris-Acetate-EDTA (TAE) buffer (Fisher Scientific,
Pittsburg, PA). The solution was boiled on the hotplate stirrer to dissolve the agarose.
The solution was cooled to approximately 50 °C and 3 μL of SYBR® Safe DNA Gel
Stain (Invitrogen, Carlsbad, CA) were added. The melted agarose was poured into a gel
tray with the well comb in place. The gel was cooled at room temperature until it was
completely solidified. The comb was removed and the tray with the gel was placed into
the electrophoresis box. The gel box was filled with 1X TAE buffer until the gel is
covered. 10 µL of 2-Log DNA Ladder (New England Biolabs, Ipswich, MA) and
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samples mixed with gel loading dye (New England Biolabs, Ipswich, MA) were loaded,
and the gel was ran at 130 V until the dye line is approximately 75–80% of the way down
the gel. The DNA fragments were visualized using the device with UV excitation,

Figure 17. Gel electrophoresis of DNA fragments visualized in UV excitation
PCR products were purified using MinElute PCR Purification Kit (Qiagen, Valencia,
CA).
Purified PCR products were ligated at 50 ºC for 30 min using NEBuilder HiFi DNA
Assembly Master Mix (New England Biolabs, Ipswich, MA) (See Table 4).
Table 4. Gibson Assembly reaction.
Insert:Vector Molar Ratio

0.025:1

Linearized pJBL7010

3 µL (0.075 pmol)

PCR PreQ1

0.3 µL (0.225 pmol)

NEB Master Mix

10 µL

Water

6.7 µL
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2 µL of the reaction were used to transform DH5α chemically competent E. coli cells
(Invitrogen, Carlsbad, CA). Cells were thawed and gently mixed. 100 µL of competent
cells were aliquoted to chilled polypropylene tubes. The ligated reactions were diluted 5fold in 10mM Tris-HCL and 1mM EDTA 1 µL of dilution was added to the cells. The
cells were incubated for 30 minutes, then heat shocked for 45 seconds in 42ºC water bath,
then placed on ice for 2 minutes. 0.9 mL of room temperature S.O.C. Medium (Cat. No.
15544-034) was added. The cells were then shaken at 225rpm (37ºC) for 1 hour. The
cells were grown overnight on LB-agar plates supplemented with antibiotic (100 μg/mL
of ampicilline). Formed colonies were picked from the plate, and each colony was
transferred into 5 mL of LB media supplemented with antibiotic and grown overnight.
The cells were collected by centrifugation; and plasmids were purified using QIAprep
Spin Miniprep Kit (Qiagen, Valencia, CA). The sequences of purified plasmids were
verified by DNA sequencing (Eurofins Genomics LLC, Louisville, KY). The plasmid
map of the resulting construct (pPreQ1-sfGFP) is shown in Figure 18.
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Figure 18. Plasmid map of pPreQ1-sfGFP. The plasmid contains PreQ1 riboswitch
sequence placed upstream of sfGFP encoding gene under control of bacterial J23119
promoter, β-lactamase encoding gene (bla) responsible for resistance to ampicillin.

Plasmid pPreQ1 variant-sfGFP. To create plasmids containing PreQ1 riboswitch
variants upstream of sfGFP encoding pJBL7010 was linearized as described above. Each
of PreQ1 riboswitch variant sequence was amplified in PCR reaction from a single
stranded DNA template using forward (5’CTCAGTCCTAGGTATAATACTAGTAAGTGAAAAAATTGAAG-3’) and reverse
(5’- GTTCTTCACCTTTGCTCATAGTTTGCTCCTG-3’) primers. Full description of
DNA templates is presented in Table 5.
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Table 5. Sequences of DNA templates for amplification of PreQ1 riboswitch variants

PCR reactions were performed in 50 µl volume as described above. The equipment used
and the PCR products are shown in Figures 19 & 20 respectively. The thermocycling
conditions are presented in Table 6.
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Figure 19: Thermocycler used through Wright Patterson Air Force Base

Figure 20: PCR Products
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Table 6. Thermocycling conditions for amplification of PreQ1 riboswitch variants.
Number of Cycles
Program
1

98 ºC for 30 s

29 cycles

98 ºC for 10 s, 53 ºC for 30 s, 72 ºC for 5

1

s

End

72 ºC for 10 min
4 ºC

PCR products were analyzed by standard 1% agarose gel electrophoresis (See Figure 21
& 22).

Figure 21. Gel electrophoresis of variant amplifications
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Figure 22: Gel Electrophoresis of PreQ1 amplification

Purified PCR products were ligated at 50 ºC for 30 min using NEBuilder HiFi DNA
Assembly Master Mix (New England Biolabs, Ipswich, MA) (See Table 7).
Table 7. Gibson Assembly reaction.
Insert:Vector Molar Ratio

0.025:1

Linearized pJBL7010

3 µL (0.075 pmol)

PCR PreQ1 variant

0.3 µL (0.225 pmol)

NEB Master Mix

10 µL

Water

6.7 µL

2 µL of each reaction were used to transform DH5α chemically competent E. coli cells
(Invitrogen, Carlsbad, CA) as described above. The cells were grown overnight on LBagar plates supplemented with antibiotic (100 μg/mL of ampicillin). Formed colonies
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were picked from the plates, and each colony was transferred into 5 mL of LB media
supplemented with antibiotic and grown overnight. The cells were collected by
centrifugation; and plasmids were purified using QIAprep Spin Miniprep Kit (Qiagen,
Valencia, CA). The sequences of all constructs have been verified by DNA sequencing at
the Eurofins Genomics LLC (Louisville, KY). See Figures 23 & 24 for formed colonies.

Figure 23: Formed colonies from Gibson Assembly

Figure 24: Formed colonies from Gibson Assembly under UV Excitation

3.4 Cell- free extract and cell- free reactions:
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Cell extract and reagents were prepared based on previously described methods and were
provided by the AFRL mentor. The final cell-free reaction based on S12 extract was
composed of the following reagents: 8 mM magnesium glutamate; 10 mM ammonium
glutamate; 130 mM potassium glutamate; 1.2 mM ATP; 0.850 mM each of GTP, UTP,
and CTP; 0.034 mg/mL folinic acid; 0.171 mg/mL yeast tRNA; 2 mM amino acids; 30
mM PEP; 0.33 mM NAD; 0.27 mM CoA; 4 mM oxalic acid; 1 mM putrescine; 1.5 mM
spermidine; 57 mM HEPES; 30% S12 extract by volume; plasmid DNA 20 ng/µL and
water.
To activate the riboswitch, cell-free reactions were treated with appropriate
concentrations of pre-queuosine1 dihydrochloride (PreQ1) in DMSO (see Results
section). Equivalent volume of DMSO was added to the reactions for riboswitch in
“OFF” state.
To test activation of riboswitch variants, cell-free reactions were treated with appropriate
concentrations of cortisol or dehydroepiandrosterone sulfate (DHEAS) in DMSO or with
appropriate concentrations of dopamine or norepinephrine in water. Equivalent volume of
DMSO or water was added to the reactions for riboswitch in “OFF” state.
All cell-free reactions were prepared on ice in triplicates at the 12 µL scale. 45 µl of a
mixture containing the desired reaction components was prepared and the 12 µL was
pipetted into three wells of 384-well clear bottom black walled plate (Corning), taking
care to avoid bubbles. The plate was sealed with an oxygen impermeable membrane to
prevent evaporation. Reactions were incubated for 18 hours at 30º C and monitored using
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a SpectraMax Paradigm Plate Reader (Molecular Devices), measuring fluorescence every
10 minutes at 470 nm excitation and 510 nm emission wavelengths for sfGFP.
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4. Results & Discussion
4.1 Chemical Structure
The software NUPACK was used to simulate the chemical structure [90]. The input
requirements are in terms of DNA sequence to output the structure and chemical
properties. Figure 25 shows the simulated results for PreQ1, by the software. In Figure 25,
the structure of PreQ1 is shown on the left column showing the identity and the
equilibrium probability for each position whereas the right column in this figure shows
the helicity of this aptamer. The different nucleotides, A, C, G, and T, form the loop
shown in Figure 25 and based on their sequence determines hydrogen bonding,
equilibrium probabilities, and potential ligand binding [46]. The DNA configuration can
be broken down into loops, which are scored in terms of free energy. In Figures 25 and
26, the free energy that is stated is the sum of the secondary loops. The secondary loops
impact ligand bonding. The probability shown is the probability of the sequence to be in
that formation. The ensemble defect is the average number of nucleotides that are
incorrectly paired. For this number, 0 is the best and N would be the worst. Normalized
ensemble defect is the percentage of this with 0% being the best and 100% being the
worst. PreQ1 will be the structure that the variants will be compared to, as PreQ1 is
already an established riboswitch.
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Figure 25. NUPACK simulation of PreQ1 with identity and equilibrium probability
shown to the left. To the right shows the helicity.

Figure 26. Structure properties for PreQ1 made by NUPACK
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As it is shown, the PreQ1 structure has strong equilibrium probabilities throughout the
loop. In the details it shows that 22 nucleotides are being examined in the aptamer
domain. The details also show that there is a 0.326 probability that aptamer domain
would present this way. A 15.3% normalized ensemble defect is also shown through this
design structure. These details are then compared to the structures that were designed to
loop this way versus a design where it naturally occurs.
In addition to simulating the free energy structure, NUPACK can take input on
the structure. This allows for riboswitches to be designed and show the properties for the
structure. In the following figures, Figures 27-34, each variant is shown and was designed
how PreQ1 is naturally. The properties are shown for each design in Figures 28, 30, 32,
and 34.
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Figure 27. NUPACK design of Variant 1 with identity and equilibrium.

Figure 28. Structure properties for Variant 1 made by NUPACK

Figure 29. NUPACK design of Variant 2 with identity and equilibrium.
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Figure 30. Structure properties for Variant 2 made by NUPACK

Figure 31. NUPACK design of Variant 3 with identity and equilibrium.
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Figure 32. Structure properties for Variant 3 made by NUPACK

Figure 33. NUPACK design of Variant 4 with identity and equilibrium.
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Figure 34. Structure properties for Variant 4 made by NUPACK

The results above show the four variant designs of PreQ1 that were designed. The
variants equilibrium probabilities show different probabilities than the original. Variants
1 and 2 are most different with multiple green and blue tones in Figures 27 and 29,
indicating they have a lower probability of this structural formation. Variants 3 and 4
have differences in comparison to the original, but they keep to a closer probability as the
original. From the equilibrium probability it is expected that variants 3 and 4 will respond
similarly to PreQ1.
The NUPACK result details for each structure provide the probability for the
formation of each structure. For the original structure of PreQ1 there is a 0.326
probability. For variant 1 the probability is 0.170, variant 2 the probability is 0.166,
variant 3 the probability is 0.120, and variant 4 the probability is 0.016. For these details,
the riboswitch aptamer is not bonded to a ligand. This means in the presence of a ligand;
the probabilities could be different than a computational model. The probability
equilibrium is more accurate, due to it being based on the pairing probabilities. The
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closest probabilities to the original will most likely react similarly to a ligand. The
following results are experimental results.
4.2 Riboswitch Activation Time Results
In this section, the results of each analyte tested against the original PreQ1, and
variants is shown (Figure 35-43). In each graph a line represents a riboswitch activation
over time. The activation is measured by the excitation and emission fluoresce (excitation
at 470nm and emission at 510nm). When the solution of the RNA mixture with either an
analyte or control, the RFU value over time will have a linear trend. As the solution
balances out and the ligand binds, the RFU plateaus. The following figures show this
trend. The peak and plateau level depicts if the riboswitch is transcribing proteins or
terminated.
A test was run for the riboswitch being OFF in water and DMSO for comparison
with each analyte. PreQ1, DHEA-S, and cortisol are compared against the OFF state with
DMSO. The other biomarkers are compared against the OFF state with water. These
graphs show the variants response with respect to the original design. The OFF state is
when the aptamer is not bonded to a ligand. When the analyte is added, the riboswitch
aptamer binds. The analyte or biomarker is the ligand in this occurrence. The riboswitch
is then in an ON state. When no ligand is present, PreQ1’s expression platform is
transcribing, which explains the OFF state having higher relative fluorescence units
(RFU). This is shown with the OFF (DMSO) having a peak around 2.50*107 and preQ1 is
close to zero.
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Figure 35. Riboswitch time log with OFF DMSO
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Figure 36. Riboswitch time log with PreQ1
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Figure 37. Riboswitch time log with DHEA-S
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Figure 38. Riboswitch time log with Cortisol
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Figure 39. Riboswitch time log with OFF Water
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Figure 40. Riboswitch time log with Epinephrine
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Figure 41. Riboswitch time log with Norepinephrine
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Dopamine
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Figure 42. Riboswitch time log with Dopamine
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Figure 43. Riboswitch time log with Serotonin

The graphs above show the variants over time with reference to the preQ1, while
the date shown in Biomarker Results show the peak of each variant ON to OFF.
4.3 Biomarker Results
The following figures, Figure 44-50, show the riboswitch peak activation results
from the Time Response data above. This data is extracted from the time activation
graphs when the riboswitch peaks and levels off. The bar graphs are comparing PreQ1 as
the original riboswitch and each of the variants with the two bars showing an OFF versus
ON. The difference in the bar values show how the riboswitch is transcribing or
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terminated. In the figures, the orange bars will represent the OFF state and the blue bars
will represent the ON state. When the riboswitch is OFF, the ligand is not attached to the
aptamer, and the gene expression is on. When the riboswitch is ON, the ligand is attached
to the aptamer, and the expression is terminated. This is shown from the OFF being
higher than the ON. This is expected due to the gene expression being on when the
aptamer is not attached to the ligand. Variants 1 and 2 do not follow this by the ON, when
the ligand is bonded, being higher.
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Figure 44. PreQ1 biomarker against original riboswitch and variants

PreQ1 is an example of how the riboswitch should respond. The following biomarkers
that were tested are being compared to the original riboswitch, as well as the above
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figure. DHEA-S shows a difference with how the variants all follow the original
riboswitch response. Variants 1 and 2 did not follow the original response with the preQ1
analyte though. Due to a different relationship with PreQ1 and DHEA-S for variants 1
and 2, the Variant Response is shown to expand on this.
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Figure 45. DHEA-S biomarker against original riboswitch and variants

The following figures differ from preQ1 by the ON state being higher than the OFF state.
In cases when variant 3-7 responds differently than the original, it could be due to error.
This is shown in cortisol, where variant 6 is slightly higher in the OFF state than ON. The
standard deviation is shown by the bars in the figures for this. This is also shown in
serotonin with variant 4 and epinephrine with variants 3 and 4.
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Figure 46. Cortisol biomarker against original riboswitch and variants
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Figure 47. Serotonin biomarker against original riboswitch and variants
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Figure 48. Dopamine biomarker against original riboswitch and variants
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Figure 49. Epinephrine biomarker against original riboswitch and variants
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Figure 50. Norepinephrine biomarker against original riboswitch and variants

4.4 Variant Results
In this section, PreQ1, Variant 1, and Variant 2 are expanded. The following
figures, Figure 51-53, take the data that was presented above and show the riboswitches
Original, Variant 1, and Variant 2 response with each analyte in the same figure. The bars
follow the same pattern as above with orange bar is OFF, and the blue bar is ON. Variant
1 and 2 responses are compared to PreQ1. The focus on this is looking at the aptamer of
the riboswitch binding to the PreQ1 and DHEA-S ligand. The response shows preQ1 and
DHEA-S respond the same with the original PreQ1 riboswitch but differs in variant 1 and
2. In PreQ1’s response, the relationship of OFF to ON is OFF being higher with PreQ1
and DHEA-S and ON higher for all others. The difference with Variants 1 and 2 response
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is that DHEA-S follows the original, but PreQ1 does not. Due to this a dosage test was
conducted. The results are shown below in the Dosage Results for Variants 1 and 2
section.
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Figure 51. PreQ1 riboswitch against different biomarkers
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Figure 52. Variant 1 riboswitch against different biomarkers
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Figure 53. Variant 2 riboswitch against different biomarkers
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4.5 Dosage Results for Variant 1 and 2
In this section, variants 1 and 2 are shown with different concentrations of
DHEA-S. For both responses, there is a downward tread with a higher concentration of
DHEA-S. The following figures, Figure 54 and 55, show variant 1 and 2 response to
different concentrations of DHEA-S. The concentrations used for the dose response are
concentrations found in the body.

Variant 1 DHEA-S Dose Response

y = -3E+06x + 3E+07

RFU (Ex: 470nm; Em: 510nm)

3.50E+07

3.00E+07
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5.00E+06
0.00E+00
0
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31.25

62.5

125

250
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Figure 54. Variant 1 against DHEA-S Dose Response
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Figure 55. Variant 2 against DHEA-S Dose Response

In the above figures, Figure 54 and 55, the drug response may be described by a linear fit.
Drug dose and response is mathematically represented in terms of a sigmoidal function.
Such function allows generation of a S curve that plots the behavior from a lower point
(usually negative to positive) to higher. Thus, the S curve. Since the physiologic behavior
represents only the positive concentration, studied in this paper, the dose characteristics
are described by a linear equation as the figure shows. Each on the trendline fit shows a
negative slope.1
As it shows on Figure 54 and 55, the equations have a negative linear trend. This is due to
the riboswitch having a higher RFU since there is no DHEA-S and the riboswitch being
OFF and transcribing proteins. Comparing these graphs to the time activation graphs and
biomarker graphs for DHEA-S and PreQ1, the trendlines follow the same pattern. As the
concentration of the analyte increases, the variants are showing how they terminated their
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protein production. If this was PreQ1 as the analyte, the production would stay the same
as the concentration increases.
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5. CONCLUSION
This research describes the methods of reengineering riboswitches. In this
experimentation, PreQ1 was examined and engineered into four new variants. Through
the computational and experimental procedures that were conducted, it is shown that two
of these variants responded to DHEA-S differently than PreQ1. From reference research,
three variants were tested with the same procedures and showed no new data. In
conclusion, it can be confirmed that riboswitches can be reengineered to respond to
different biomarkers.
Based on the presented data analysis above, it can be concluded that variants 1
and 2 were reengineered to respond to DHEA-S when the original riboswitch did not.
The computational data confirms this through variants 1 and 2 having equilibrium
probabilities that indicate the structural formation would not be likely. Variants 3 and 4
indicated to show results similar to PreQ1 based on their equilibrium probability. This is
also shown through the response of variants 1 and 2 differing when testing against PreQ1.
All variants had similar results when presented with the aptamer PreQ1. This change did
not affect the response against DHEA-S though. Due to this, a closer examination was
done through a dose response test. This test confirmed this conclusion, by having a
downward tread as the concentrations of DHEA-S increased.
Continuing this research can be done by looking at different biomarkers with the
variants that were used in this research. The riboswitch, PreQ1, can also be reengineered
with different variants. Along with those suggestions, the designing by computer
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software’s can be used with part research to help confirm variant riboswitches that were
based off known riboswitches.
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